PMSF

PMSF (Phenylmethylsulfonyl fluoride) is a nonspecific and irreversible serine proteases inhibitor. PMSF inhibits some thiol proteases, non-protease enzymes, and acetylcholinesterase. PMSF can be used to prepare protein extracts from tissue and cell lysates^[1][2][3][4]. In Vitro:PMSF (2 mM) inhibits carbachol-stimulated inositol phosphate accumulation in the presence of Li⁺ by only 15%-19%. PMSF inhibition of phosphoinositide turnover is due to one or more steps following phosphoinositide breakdown^[1]. PMSF inhibits the acylation of the inositol residue of GPI intermediates in bloodstream-form T. brucei. PMSF inhibits the formation of glycolipid C but does not inhibit fatty acid remodeling in vitro. PMSF inhibits GPI acylation and ethanolamine phosphate addition in procyclic trypanosomes but not in Hela cells^[2]. In Vivo:PMSF (0.1 mL/10 g b.wt, i.p.) produces antinociception as indicated by the dose-responsive increase in % MPE in the tail-flick latency evaluation, but fails to produce a clear dose-responsive inhibition of locomotion. Mice receiving i.p. injections of PMSF exhibit cannabinoid effects that includes antinociception, hypothermia and immobility with ED₅₀ values of 86, 224 and 206 mg/kg, respectively. PMSF (30 mg/kg) pretreatment potentiates the effects of anandamide on tail-flick response (antinociception), spontaneous activity and mobility by 5-, 10- and 8-fold, respectively^[3].